Financial Performance - The company's revenue for Q3 2021 was ¥78,306,085.94, representing a 24.44% increase year-over-year[3] - The net profit attributable to shareholders was -¥12,536,578.53, a decrease of 270.01% compared to the same period last year[3] - The basic earnings per share were -¥0.08, reflecting a decline of 260.00% year-over-year[3] - The total operating revenue for Q3 2021 was ¥252,150,180.35, an increase of 4.87% compared to ¥240,978,663.96 in the same period last year[33] - The net profit for Q3 2021 was a loss of ¥6,130,103.51, compared to a profit of ¥43,258,069.73 in Q3 2020, representing a significant decline[35] - The basic earnings per share for Q3 2021 was -¥0.04, compared to ¥0.30 in Q3 2020, indicating a significant drop[35] Assets and Liabilities - Total assets increased by 23.23% to ¥1,198,395,248.61 compared to the end of the previous year[4] - The company's total assets increased to ¥1,198,395,248.61 in Q3 2021 from ¥972,502,779.28 in the previous year, marking a growth of 23.23%[31] - The total liabilities rose to ¥456,058,223.90 in Q3 2021, compared to ¥202,559,099.70 in the same period last year, indicating a growth of 125.61%[31] - The total equity attributable to shareholders reached ¥765,148,250.51, while total equity including minority interests was ¥769,943,679.58[45] Cash Flow - The cash flow from operating activities showed a net amount of ¥318,591.85, down 99.55% year-to-date[3] - The net cash flow from operating activities for the current period is CNY 318,591.85, a significant decrease from CNY 71,244,791.39 in the previous period[39] - Cash inflow from operating activities totaled CNY 283,909,384.26, down 3.5% from CNY 293,219,513.42 in the previous period[38] - Cash outflow from operating activities increased to CNY 283,590,792.41, compared to CNY 221,974,722.03 in the previous period, reflecting a 27.8% rise[38] - The net cash flow from investing activities is CNY -237,272,237.01, a decline from CNY 82,303,316.61 in the previous period[39] - The net cash flow from financing activities improved to CNY 164,938,738.37, compared to a net outflow of CNY -58,775,055.23 in the previous period[39] Inventory and Investments - The company reported a significant increase in inventory, which rose by 33.76% to ¥71,597,014.95[8] - The long-term equity investments decreased to ¥42,498,542.60 from ¥56,669,473.21, a decline of 25.00%[31] - Research and development expenses for Q3 2021 were ¥19,888,731.45, up 19.00% from ¥16,711,165.89 in the previous year[34] Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,200[13] - Shanghai Kangyi Investment Co., Ltd. holds 30.43% of shares, totaling 47,291,400 shares[13] - The top ten shareholders hold a significant portion of shares, with the largest shareholder holding over 30%[13] Project Developments - The project for producing 1,200 tons of active bacterial peptide premix and 1,200 tons of veterinary raw materials has been delayed and is now expected to be completed by March 31, 2022[16] - The company is investing approximately RMB 201.17 million in a cogeneration project to ensure stable heating quality and reduce energy costs[17] - The main construction of the cogeneration plant has been completed, and it is currently undergoing acceptance testing before grid connection[17] - The company has faced delays in project construction due to the COVID-19 pandemic and rising raw material costs[15] Fundraising Activities - The company plans to issue convertible bonds with a total fundraising amount not exceeding 305 million yuan, with the investment amount adjusted to 430.686 million yuan[18] - The company received acceptance from the China Securities Regulatory Commission (CSRC) for its application to publicly issue convertible bonds on November 16, 2020[19] - The company decided to terminate the public issuance of convertible bonds due to changes in the external market environment and the impact of the overseas pandemic[21] - The company approved a non-public stock issuance plan on January 23, 2021, aiming to raise up to 305 million yuan[22] - The non-public stock issuance will involve issuing no more than 46,624,751 shares, accounting for 30% of the total share capital before the issuance[22] - The CSRC approved the company's non-public stock issuance on June 16, 2021, allowing the issuance of up to 46,624,751 new shares[24] Business Structure Optimization - The company completed the deregistration of its wholly-owned subsidiary, Green康 Hong Kong, to optimize its business structure and reduce management costs[26] Cash and Cash Equivalents - As of September 30, 2021, the company's cash and cash equivalents amounted to approximately 121.97 million yuan, down from 194.26 million yuan at the end of 2020[28] - The total cash and cash equivalents decreased by CNY 72,293,497.73, contrasting with an increase of CNY 93,675,190.19 in the previous period[39]

Financial Performance - The company's operating revenue for the first half of 2021 was ¥173,844,094.41, a decrease of 2.36% compared to ¥178,051,590.46 in the same period last year[22]. - The net profit attributable to shareholders of the listed company was ¥6,565,087.10, down 81.69% from ¥35,863,013.15 in the previous year[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥6,658,132.49, a decrease of 77.77% compared to ¥29,946,701.23 in the same period last year[22]. - The net cash flow from operating activities was -¥18,353,447.83, a decline of 140.18% from ¥45,680,267.40 in the previous year[22]. - Basic earnings per share were ¥0.04, down 82.61% from ¥0.23 in the same period last year[22]. - Operating costs increased by 21.95% to ¥132,288,616.56 from ¥108,480,530.66 year-on-year[38]. - Research and development expenses rose by 23.79% to ¥12,579,486.73, up from ¥10,161,593.02 in the previous year[38]. - The company reported a significant increase in financial expenses, which rose by 324.42% to ¥1,024,849.50, primarily due to exchange losses[38]. - The company reported a total non-operating loss of ¥3,250,284.42 after tax effects and minority interests[26]. - The company reported a total revenue of 600 million yuan for the first half of 2021, with a year-on-year increase of 86.82%[102]. Assets and Liabilities - Total assets at the end of the reporting period were ¥999,216,099.69, an increase of 2.75% from ¥972,502,779.28 at the end of the previous year[22]. - The net assets attributable to shareholders of the listed company were ¥750,236,905.08, a decrease of 1.95% from ¥765,148,250.51 at the end of the previous year[22]. - The company's current assets decreased to RMB 195,356,705.83 from RMB 304,576,512.59, representing a decline of about 36%[147]. - Total liabilities increased to RMB 244,263,204.32 from RMB 202,559,099.70, which is an increase of about 20.5%[148]. - The company's short-term borrowings surged to RMB 67,665,494.99 from RMB 5,005,270.83, reflecting a significant increase of approximately 1255%[148]. - The total equity attributable to the parent company decreased to RMB 750,236,905.08 from RMB 765,148,250.51, a decline of about 1.9%[149]. Business Operations - The company operates in three main business segments: animal health, plant protection, and food additives, with no changes in its primary business activities during the reporting period[29]. - The company has established stable partnerships with major clients, including global and domestic leaders in the animal health and agriculture sectors[35]. - The company has been recognized as a national high-tech enterprise and has received multiple awards for its technological innovations and patents, totaling 16 invention patents and 15 utility model patents as of mid-2021[31]. - The company emphasizes product quality, adhering to GMP standards, and has successfully passed various international inspections, including those by the FDA and Australian authorities[34]. - The company has developed core production technologies, including spray drying and fermentation control, ensuring product quality and market adaptability[32]. Risk Management - The company has outlined potential risks and countermeasures in its management discussion and analysis section[4]. - The company faces risks from major customer procurement fluctuations, which could significantly impact revenue and profitability[62]. - The company is addressing environmental risks by implementing wastewater treatment systems and monitoring equipment to comply with environmental regulations[64]. - The company has approved a foreign exchange hedging plan to mitigate risks from currency fluctuations, with a maximum amount of USD 5 million for hedging activities[65]. - The company plans to invest up to 30 million yuan in commodity futures hedging to mitigate raw material price volatility risks from January 1, 2021, to December 31, 2021[66]. Environmental and Social Responsibility - In the first half of 2021, the company reported a chemical oxygen demand (COD) discharge concentration of 165.002 mg/L, well below the standard limit of 350 mg/L[84]. - The ammonia nitrogen discharge concentration was recorded at 4.617 mg/L, significantly lower than the regulatory standard of 35 mg/L[84]. - The company invested a total of 8.347 million yuan in environmental equipment upgrades and training in the first half of 2021[84]. - The company’s charity foundation donated a total of 33,400 yuan to support 17 impoverished families in early 2021[86]. - The foundation also provided 6,000 yuan in living expenses for children of deceased employees during the first half of 2021[86]. Future Outlook - The company provided a positive outlook for the second half of 2021, projecting a revenue growth of 20% to 30% based on current market trends and user acquisition strategies[91]. - New product launches are expected to contribute an additional 200 million RMB in revenue by the end of 2021, focusing on innovative biopharmaceutical solutions[91]. - The company is exploring potential mergers and acquisitions to strengthen its market position, with a budget of 500 million RMB earmarked for strategic investments[91]. - The company plans to enhance its market expansion strategies and invest in new product development to drive future growth[177]. Shareholder and Corporate Governance - The company plans to issue convertible bonds to raise up to CNY 305 million, with the investment project total adjusted to CNY 430.686 million[115]. - The company has committed to repurchase shares if the stock price remains below the latest audited net asset value for 20 consecutive trading days within three years post-listing[92]. - The company will adhere to the latest regulations from the China Securities Regulatory Commission regarding compensation measures if commitments are violated[93]. - The company has established a framework for repurchase and stabilization of stock prices to ensure investor confidence[92]. - The company has no significant litigation or arbitration matters during the reporting period[100].

证券代码：002868 证券简称：绿康生化 公告编号：2021-064 绿康生化股份有限公司 关于参加 2021 年度福建上市公司投资者网上集 体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 绿康生化股份有限公司(以下简称"公司"或"绿康生化") 为进一步加强与投 资者的互动交流，使广大投资者能更深入全面地了解公司情况，本公司将参加由 福建证监局与福建省上市公司协会、深圳市全景网络有限公司举办的"2021 年 度福建上市公司投资者网上集体接待日活动"。现将有关事项公告如下： 本次投资者网上集体接待日活动将通过深圳市全景网络有限公司提供的网 上平台采取网络远程的方式进行，投资者可以登录"全景网投资者关系互动平台" （http://ir.p5w.net）参与本次投资者网上集体接待日活动，网上互动交流时间为 2021 年 5 月 14 日（星期五）15:30-17:00 。 欢迎广大投资者积极参与。 特此公告。 绿康生化股份有限公司 董事会 二〇二一年五月十日 第 1 页 共 1 页 ...

Financial Performance - The company's revenue for Q1 2021 was ¥90,930,335.34, representing a 10.21% increase compared to ¥82,505,391.38 in the same period last year[8] - Net profit attributable to shareholders decreased by 81.80% to ¥2,401,830.67 from ¥13,195,905.25 year-on-year[8] - Operating profit decreased by 90.48% to CNY 1,509,334.75 compared to CNY 15,855,120.01 in the same period last year[19] - Net profit for the current period was ¥7,189,068.19, down from ¥13,071,900.69 in the previous period, representing a decrease of 45.0%[59] - Total profit for the current period was ¥7,540,604.56, down from ¥15,321,272.00, a decrease of 50.9%[58] - Basic earnings per share for the current period were ¥0.050, compared to ¥0.11 in the previous period, a decrease of 54.5%[59] Cash Flow - The net cash flow from operating activities was negative at -¥25,012,216.19, a decline of 285.85% compared to ¥13,458,368.76 in the previous year[8] - The net cash flow from operating activities was -19,837,279.99, a decrease compared to 12,495,721.77 in the previous period[66] - Cash inflow from operating activities totaled 66,814,777.53, a decline from 89,707,822.13 in the previous period[66] - The company reported a net cash flow from investing activities of -73,556,187.37, compared to -7,810,536.97 in the previous period[66] - The net cash flow from financing activities was 27,439,799.29, compared to -26,947,198.95 in the previous period[67] Assets and Liabilities - The total assets at the end of the reporting period increased by 2.87% to ¥1,000,367,117.05 from ¥972,502,779.28 at the end of the previous year[8] - Total assets as of March 31, 2021, reached CNY 973,621,731.25, compared to CNY 944,584,726.17 at the end of 2020[48] - Total liabilities increased to CNY 229,145,939.03 from CNY 202,559,099.70 year-over-year[46] - The total assets as of the end of the period were 972,502,779.28, with total liabilities of 202,559,099.70[70] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 9,620[12] - The top shareholder, Shanghai Kangyi Investment Co., Ltd., held 30.43% of the shares, amounting to 47,291,400 shares[13] - The company repurchased 2,011,507 shares, accounting for 1.29% of total shares, with a total expenditure of CNY 32,406,447.45[27] Research and Development - R&D expenses increased by 67.40% to CNY 6,280,220.20, primarily due to higher depreciation and outsourced technical service costs[19] - Research and development expenses increased to CNY 6,280,220.20, a rise of 67.4% from CNY 3,751,575.06 in the previous year[52] - The company has invested ¥20.46 million in the project for producing 1,200 tons of active bacterial peptide premix and 1,200 tons of veterinary raw materials (sulfamethoxazole) as of March 31, 2021[31] Borrowings and Financial Expenses - Short-term borrowings surged by 761.95% to ¥43,143,125.10, primarily due to new bank loans taken during the period[18] - Financial expenses increased by 43.32% to CNY -629,813.90, mainly due to exchange rate fluctuations[19] - Long-term borrowings decreased to CNY 52,000,000.00 from CNY 57,000,000.00 year-over-year[46] Other Income and Expenses - The company recorded non-operating income of ¥1,740,532.87 from government subsidies during the reporting period[10] - Other income rose by 146.42% to CNY 1,740,905.27, mainly due to increased government subsidies[19] - The company incurred asset impairment losses of -¥1,448,226.23, compared to -¥640,868.27 in the previous period, indicating an increase in losses[58] Inventory and Receivables - The company reported a significant increase in accounts receivable, which rose by 90.49% to ¥58,039,389.21 due to increased sales in March[18] - Accounts receivable increased significantly to ¥58.04 million from ¥30.47 million, marking an increase of approximately 90.5%[42] - The company reported a significant increase in accounts receivable, which rose to CNY 49,316,976.91 from CNY 26,849,403.09 in the previous year[46] Project Updates - The project for the technical center expansion was completed and accepted by April 2020, with surplus funds of ¥50 million allocated to supplement working capital[32] - The company has postponed the completion date of the active bacterial peptide project to September 30, 2021, due to delays caused by the COVID-19 pandemic[31] Compliance and Audit - The company has not undergone an audit for the first quarter report[74] - The report indicates that the company has not applied the new leasing standards retrospectively[73]

Financial Performance - The company's operating revenue for 2020 was ¥308,145,259.54, representing a 1.44% increase compared to ¥303,759,977.46 in 2019[18]. - The net profit attributable to shareholders for 2020 was ¥43,208,315.92, a decrease of 24.15% from ¥56,966,032.34 in 2019[18]. - The basic earnings per share for 2020 was ¥0.28, down 24.32% from ¥0.37 in 2019[18]. - The overall gross profit margin for 2020 was 30.35%, a decrease of 2.91 percentage points compared to the previous year[45]. - The company reported non-operating income of ¥13,223,142.10 in 2020, down from ¥21,486,880.79 in 2019[23]. - The revenue from the veterinary medicine segment decreased by 8.87% to ¥245,077,749.01, accounting for 79.53% of total revenue[58]. - The food additive segment saw a significant increase in revenue by 116.75%, reaching ¥28,875,371.31, up from ¥13,322,217.02 in 2019[58]. Cash Dividends - The company reported a cash dividend of 1.4 yuan per 10 shares (including tax) for a total of 153,404,330 shares after deducting the repurchased shares[5]. - For the 2020 fiscal year, the company plans to distribute a cash dividend of RMB 1.4 per 10 shares, amounting to RMB 21.48 million, with a total cash dividend including other methods reaching RMB 53.90 million[115]. - The cash dividend for 2020 represents 49.70% of the net profit attributable to ordinary shareholders[114]. - The cash dividend payout ratio for 2020 is 100% of the total distributable profit[115]. - The total cash dividends distributed over the past three years have shown a consistent increase, with 2020's total cash dividends being the highest at RMB 53.90 million[114]. Assets and Liabilities - Total assets at the end of 2020 were ¥972,502,779.28, a decrease of 3.72% from ¥1,010,052,912.03 at the end of 2019[18]. - Cash and cash equivalents rose from CNY 114,313,030.64 to CNY 194,264,741.47, an increase of 69.94%, mainly due to the maturity of financial products[35]. - Accounts receivable decreased to ¥30,469,248.05, representing 3.13% of total assets, down from 4.85% in the previous year[76]. - Inventory increased to ¥53,527,140.34, accounting for 5.50% of total assets, up from 4.94% year-on-year[76]. - Long-term equity investments stood at ¥56,669,473.21, which is 5.83% of total assets, slightly up from 5.69%[76]. Research and Development - The company has accumulated 14 invention patents and 15 utility model patents by the end of 2020, showcasing its strong focus on technological innovation[37]. - Research and development expenses amounted to 19,913,133.94 CNY, representing 6.46% of the company's total revenue, an increase of 7.35% from the previous year[69]. - The number of R&D personnel increased by 6.35% to 67, although the proportion of R&D staff relative to total employees decreased slightly to 10.21%[70]. Market and Industry Trends - The veterinary medicine industry is shifting towards safer, more effective products with lower residues, driven by increasing food safety concerns globally[29]. - The global population is projected to grow from over 7 billion to 8.5 billion by 2030 and 9.7 billion by 2050, driving demand for meat, egg, and dairy products, which supports the growth of the livestock and feed industries[30]. - The global biopesticide market was valued at USD 3.3 billion in 2017 and is expected to reach USD 9.5 billion by 2025, with a compound annual growth rate (CAGR) of 15% to 18%[32]. Corporate Governance and Compliance - The company emphasizes the importance of accurate and complete financial reporting, with key executives affirming the integrity of the annual report[3][4]. - The company has committed to fulfilling its obligations regarding shareholder returns and has not engaged in any actions that would harm shareholder interests[124]. - The company has established a commitment to avoid any actions that could harm the interests of other shareholders[120]. Environmental and Social Responsibility - The company has a pollution discharge standard compliance with a chemical oxygen demand (COD) concentration of 22.14 mg/L, well below the limit of 60 mg/L[165]. - The company established a charity fund to support 19 impoverished families with a total donation of CNY 38,400 in 2020[161]. - The company invested CNY 1.2 million to cover four years of living expenses for the children of deceased employees[161]. Strategic Initiatives - The company aims to adjust its product structure and actively explore domestic and international markets in response to national strategies and policy directions[33]. - The company plans to enhance its product registration and approval processes in response to domestic regulatory changes, focusing on transitioning existing products to comply with new standards[101]. - The company is planning to expand its market presence through strategic partnerships and acquisitions in the upcoming fiscal year[156].

Financial Performance - Operating revenue for the reporting period was CNY 62,927,073.50, down 18.13% year-on-year[7] - Net profit attributable to shareholders was CNY 7,374,239.07, a decrease of 25.06% compared to the same period last year[7] - Net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 5,425,070.11, down 29.01% year-on-year[7] - Basic earnings per share were CNY 0.05, a decrease of 37.50% compared to the same period last year[7] - The weighted average return on net assets was 0.93%, a decrease of 0.40% year-on-year[7] - Cash flow from operating activities was CNY 25,564,523.99, down 28.28% compared to the same period last year[7] - Total operating revenue for Q3 2020 was CNY 62,927,073.50, a decrease of 18.1% compared to CNY 76,861,147.27 in Q3 2019[51] - Net profit attributable to the parent company for Q3 2020 was CNY 7,374,239.07, a decline of 25.0% from CNY 9,839,666.26 in Q3 2019[52] - The company reported a net profit margin of 12% for Q3 2020, reflecting improved operational efficiency[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 967,093,955.91, a decrease of 4.25% compared to the previous year[7] - The total current liabilities decreased to CNY 118,945,347.40 from CNY 137,636,933.66, a reduction of about 14%[44] - The company's long-term borrowings decreased to CNY 57,000,000.00 from CNY 77,000,000.00, reflecting a decline of approximately 26%[44] - The company's accounts receivable decreased to CNY 32,234,550.51 from CNY 49,022,979.24, a decline of about 34%[43] - Total liabilities decreased to CNY 183,971,295.87 from CNY 225,289,946.77, reflecting a reduction of 18.3%[49] - The total assets of the company are valued at CNY 1,010,052,912.03, with total equity amounting to CNY 778,502,064.53[76] Shareholder Information - The total number of shareholders at the end of the reporting period was 9,931[11] - The largest shareholder, Shanghai Kangyi Investment Co., Ltd., held 30.43% of the shares[11] - The company has repurchased 2,011,507 shares, accounting for 1.29% of total shares, with a total expenditure of ¥32,406,447.45[21] - Major shareholders have committed to not reduce their holdings by more than 25% of their total shares within two years after the lock-up period[22] - Shareholders are restricted from transferring shares for 12 months post-listing, reinforcing shareholder commitment[23] Government and Financial Support - The company received government subsidies amounting to CNY 2,441,855.96 during the reporting period[8] - Cash received from tax refunds increased by 138.64% to ¥14,259,706.90, mainly due to an increase in tax refunds[18] Investment and Projects - The company invested approximately ¥201.17 million in the cogeneration project, which is expected to enhance energy efficiency and reduce costs[19] - The company has committed to invest a total of 24,091.91 million CNY in the 2,400 tons/year active bacteria project, with 100% of the funds already utilized[30] - The technology center expansion project has a total investment of 7,725.78 million CNY, with 2,298.30 million CNY invested so far, achieving a progress rate of 92.07%[30] - The company has also allocated 5,427.48 million CNY for the technology center expansion project, with 5,000.00 million CNY already utilized, achieving a progress rate of 92.12%[30] Cash Flow and Financial Management - Cash and cash equivalents increased by 81.95% to ¥207,988,220.83 due to the maturity of financial products[15] - The company has invested a total of 42,500 million RMB in entrusted financial management, with 19,430 million RMB remaining in unexpired balances[35] - The company reported a total operating cash inflow of CNY 272,727,369.96, compared to CNY 239,706,393.46 in the previous period, reflecting a growth of 13.8%[68] Research and Development - Research and development expenses increased slightly to ¥6,455,345.96 from ¥6,361,904.79, indicating a focus on innovation[55] - The company has committed to investing 5 million in R&D for new technologies over the next year to stay competitive[25] Market Outlook and Strategy - The company provided a positive outlook for Q4 2020, projecting a revenue increase of 20% based on current market trends[25] - The company is exploring market expansion opportunities in Southeast Asia, targeting a 10% market penetration by the end of 2021[25] - A strategic acquisition is planned, with negotiations ongoing for a potential target that could enhance the company's product offerings[25]

Financial Performance - The company's operating revenue for the first half of 2020 was ¥178,051,590.46, representing a 23.97% increase compared to ¥143,624,507.33 in the same period last year[17]. - The net profit attributable to shareholders of the listed company was ¥35,863,013.15, a 40.96% increase from ¥25,441,248.51 in the previous year[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥29,946,701.23, showing an 84.07% increase from ¥16,269,514.37 year-on-year[17]. - The net cash flow from operating activities was ¥45,680,267.40, up 56.07% from ¥29,269,595.53 in the same period last year[17]. - The basic earnings per share increased to ¥0.23, a rise of 9.52% compared to ¥0.21 in the previous year[17]. - The overall gross margin for the first half of 2020 was 39.07%, an increase of 8.40 percentage points compared to the same period last year[44]. - The company’s domestic market revenue grew by 3.29% despite regulatory impacts, supported by the promotion of food additives and pesticide products[44]. - The revenue from veterinary drugs accounted for 84.54% of total operating revenue, amounting to 150.53 million yuan, with a year-on-year growth of 19.15%[61]. Assets and Liabilities - Total assets at the end of the reporting period were ¥938,735,735.06, down 7.06% from ¥1,010,052,912.03 at the end of the previous year[17]. - The net assets attributable to shareholders of the listed company decreased to ¥757,803,358.82, a decline of 2.15% from ¥774,434,087.11 at the end of the previous year[17]. - Cash and cash equivalents increased to ¥89,741,365.60, representing 9.56% of total assets, up from 6.80% in the same period last year, a 2.76% increase[68]. - Accounts receivable rose to ¥48,819,666.07, accounting for 5.20% of total assets, an increase of 0.50% compared to the previous year[68]. - Inventory increased to ¥50,787,678.96, making up 5.41% of total assets, up from 4.05%, a 1.36% increase year-over-year[68]. - Long-term equity investments reached ¥56,201,392.13, representing 5.99% of total assets, an increase of 1.02% from the previous year[68]. - The company's total liabilities decreased to ¥175,800,607.36 from ¥231,550,847.50, indicating a reduction of approximately 24%[182]. Research and Development - The company has obtained 11 invention patents and 15 utility model patents as of June 30, 2020, reflecting its strong R&D capabilities[36]. - Research and development expenses rose by 24.69% to 10.16 million yuan, up from 8.15 million yuan year-on-year[59]. - The company is actively pursuing the registration of feed additive products as veterinary drugs to adapt to regulatory changes in the domestic market[46]. - The company has upgraded its production line for natamycin to meet customer demands and is expanding sales channels to increase market share[47]. Market and Industry Trends - The global demand for safe, efficient, and low-residue veterinary drugs is increasing, driven by heightened food safety awareness and regulatory scrutiny[30]. - The continuous growth of the livestock and feed industries presents significant market opportunities for the veterinary drug sector, with global population expected to reach 8 billion by 2025[31]. - The global biopesticide market reached $3.3 billion in 2017 and is expected to grow to $9.5 billion by 2025, with a CAGR of 15% to 18%[32]. - The promotion of biopesticides is seen as a future trend in the pesticide industry, contributing to sustainable agricultural development[32]. Risk Management - The company emphasizes the importance of risk management and has detailed potential risks and countermeasures in the report[4]. - The company faces risks from the COVID-19 pandemic, which has increased global economic uncertainty and may impact sales of exported products[100]. - The company is also exposed to risks from major customers, particularly fluctuations in procurement plans from a key client, which can significantly affect revenue and profitability[100]. - The company faces risks from changes in industry policies, particularly regarding the use of drug feed additives, which may lead to short-term uncertainty in downstream demand[101]. - The company is exposed to environmental risks as it operates in a heavily polluting industry, facing pressure related to waste emissions and environmental management[101]. Corporate Governance and Shareholder Relations - The company has committed to avoid related party transactions during the period of being a controlling shareholder or actual controller, ensuring fair and reasonable pricing based on market standards[110]. - The company has pledged to repurchase shares if the stock price remains below the latest audited net asset value for twenty consecutive trading days within three years post-IPO[110]. - The company will disclose any failure to fulfill commitments and take measures to protect investors' rights[110]. - The company’s controlling shareholder has promised to vote in favor of share repurchase plans to stabilize stock prices[110]. Social Responsibility - The company has established a poverty alleviation fund, actively participating in social responsibility initiatives to support underprivileged communities[143]. - The company donated a total of 38,000 RMB to assist 19 impoverished families through its "Love Fund" in early 2020[144]. - The company provided 192,100.5 RMB worth of pandemic prevention materials since the outbreak of COVID-19[144]. - The company allocated 40,000 RMB to support new rural construction in various towns in Pucheng County during the first half of 2020[144].

Financial Performance - The company's revenue for Q1 2020 was ¥82,505,391.38, representing a 21.63% increase compared to ¥67,835,010.75 in the same period last year[7]. - Net profit attributable to shareholders was ¥13,195,905.25, up 22.55% from ¥10,768,027.84 year-on-year[7]. - The net profit after deducting non-recurring gains and losses was ¥11,189,425.09, reflecting a 22.24% increase from ¥9,153,663.93 in the previous year[7]. - The company's operating revenue for Q1 2020 was ¥82,505,391.38, representing a 21.63% increase compared to ¥67,835,010.75 in Q1 2019, primarily due to increased purchases from major export customers[16]. - The company’s operating profit for Q1 2020 was ¥15,854,920.01, a 42.04% increase from ¥11,162,625.66 in Q1 2019, driven by revenue growth[16]. - The company reported a significant increase in investment income, rising by 36.80% to ¥733,120.64 from ¥535,904.58, due to higher returns from financial products[16]. - The total comprehensive income for the quarter was CNY 13,199,553.63, compared to CNY 10,768,027.84, marking an increase of about 22.5%[49]. - Total operating costs amounted to CNY 67,748,674.04, rising from CNY 59,985,991.07, which represents an increase of approximately 13.9%[48]. Cash Flow and Assets - The net cash flow from operating activities was ¥13,458,368.76, an increase of 11.71% compared to ¥12,047,245.50 in the same period last year[7]. - The company reported a net cash inflow from the disposal of fixed assets and other long-term assets of ¥3,280,000.00, resulting from land return payments from the local resource bureau[17]. - As of March 31, 2020, the company's cash and cash equivalents amounted to ¥98,700,925.89, a decrease from ¥114,313,030.64 on December 31, 2019, representing a decline of approximately 13.9%[38]. - The total current assets decreased to ¥512,041,151.17 from ¥586,271,692.09, indicating a reduction of about 12.6%[38]. - The company's accounts receivable increased to ¥53,736,955.67 from ¥49,022,979.24, reflecting an increase of approximately 5.5%[38]. - The total assets at the end of the reporting period were ¥953,756,042.44, down 5.57% from ¥1,010,052,912.03 at the end of the previous year[7]. - Total liabilities decreased from CNY 231,550,847.50 to CNY 189,624,866.87, showing a decline of approximately 17.9%[40]. - The company reported a decrease in accounts payable from CNY 41,821,597.57 to CNY 35,405,403.87, a reduction of about 15.5%[40]. Shareholder Information and Commitments - The total number of ordinary shareholders at the end of the reporting period was 11,454[11]. - The largest shareholder, Shanghai Kangyi Investment Co., Ltd., held 30.32% of the shares, amounting to 36,378,000 shares[11]. - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of listing, with a strict adherence to this commitment[20]. - Major shareholders are restricted from transferring or managing their shares for 12 months post-listing, ensuring compliance with this commitment[21]. - The company has a voluntary lock-up commitment where annual share reductions will not exceed 25% of the total shares held[21]. - The company has established a clear framework for compliance with shareholding commitments to enhance investor confidence[21]. - The controlling shareholder pledged to disclose any failure to fulfill commitments and take measures to protect investor rights[22]. Investment and Financial Strategy - The company has initiated a share repurchase plan with a total amount not less than ¥32.4 million and not exceeding ¥64.8 million, with a repurchase price not exceeding ¥18 per share[18]. - The company committed to a share repurchase plan approved by the shareholders' meeting to stabilize stock prices over the next three years[23]. - The company plans to continue using idle funds for purchasing financial products, indicating a strategy focused on optimizing asset management[30]. - The company has no intention of interfering with the management activities or harming the interests of the company[24]. - The company has confirmed that it will not seek to participate in actual management decisions or become the actual controller of the company[24]. Compliance and Governance - There were no violations regarding external guarantees during the reporting period, reflecting sound financial governance[32]. - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties, ensuring financial integrity[33]. - The company committed to avoiding any related party transactions that could harm the interests of other shareholders[22]. - The company is implementing new revenue and leasing standards starting in 2020, which may impact financial reporting[67].

Financial Performance - The company's operating revenue for 2019 was CNY 303,759,977.46, a decrease of 11.77% compared to CNY 344,291,893.87 in 2018[16] - The net profit attributable to shareholders for 2019 was CNY 56,966,032.34, down 23.73% from CNY 74,689,446.35 in the previous year[16] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 35,479,151.55, a decline of 34.57% from CNY 54,225,894.20 in 2018[16] - The net cash flow from operating activities was CNY 74,087,742.26, which is 11.48% lower than CNY 83,697,141.30 in 2018[16] - Basic earnings per share for 2019 were CNY 0.47, a decrease of 24.19% from CNY 0.62 in the previous year[16] - The overall gross margin for 2019 was 33.26%, a decrease of 1.28 percentage points from the previous year[45] - The total profit and net profit attributable to shareholders were ¥66,006,630.21 and ¥56,966,032.34, representing declines of 24.24% and 23.73% respectively[45] Assets and Liabilities - Total assets at the end of 2019 reached CNY 1,010,052,912.03, an increase of 25.88% compared to CNY 802,418,344.36 at the end of 2018[17] - The net assets attributable to shareholders were CNY 774,434,087.11, reflecting a growth of 4.60% from CNY 740,369,575.05 in 2018[17] - Cash and cash equivalents increased from CNY 68,689,089.35 to CNY 114,313,030.64, a growth of 66.42%, mainly due to increased loans[34] - Other receivables surged from CNY 1,467,743.89 to CNY 40,421,274.76, a staggering increase of 2653.97%, attributed to land compensation and export tax rebates[35] - Long-term borrowings reached ¥77,000,000.00, accounting for 7.62% of total assets, primarily due to loans for the cogeneration project[76] Revenue Sources - The revenue from veterinary medicine accounted for 88.53% of total revenue, amounting to ¥268.93 million, down 13.56% from ¥311.12 million in 2018[57] - Domestic sales revenue increased by 16.52% as the company adjusted its product structure in response to regulatory changes[45] - Export revenue declined by 23.69% due to significant changes in the procurement plans of major client, M.S. Technologies[45] Research and Development - The company has obtained a total of 10 invention patents and 15 utility model patents by the end of 2019, showcasing its strong R&D capabilities[37] - The company plans to enhance its product structure by developing "safe, efficient, low/no residue, and poultry-specific" veterinary raw materials and formulations[46] - Research and development expenses increased by 27.35% to ¥18,549,953.82, representing 6.11% of the company's total revenue[69] Investments and Expansion - The company invested ¥4,600 million in a pharmaceutical industry fund to target high-growth health projects[48] - The company established a joint venture, Fujian Green Home Biotechnology Co., Ltd., with an investment of ¥5.1 million, focusing on nutritional feed additives[47] - The company’s construction projects include a production capacity of 1,200 tons of active bacterial peptide premix and veterinary raw materials, indicating significant market expansion efforts[34] Risk Factors - The company has identified potential risks in its future development outlook, which investors should be aware of[5] - The company faces risks including major customer dependency, with significant fluctuations in procurement plans from key client, Masterton[107] - Environmental regulations pose a risk as the veterinary drug industry is classified as a heavily polluting sector[107] Corporate Governance - The company has committed to not transferring or entrusting others to manage its shares for 36 months from the date of listing, with strict adherence to this commitment[119] - Major shareholders are restricted from reducing their holdings for two years after the lock-up period, with a maximum annual reduction of 25% of their total shares[120] - The company has established a voluntary lock-up period for its shares, ensuring stability in the market post-IPO[120] Social Responsibility - The company provided assistance to 17 impoverished families through its "Love Fund" in 2019, donating a total of 34,400 yuan[162] - The company donated 100,000 yuan to the Nanping Charity Association in 2019[162] - The company plans to continue its "New Rural Construction" poverty alleviation program, actively engaging in local government initiatives[165] Environmental Compliance - The company has established a wastewater treatment workshop to handle wastewater, ensuring compliance with urban sewage treatment standards[168] - The company received approval for its environmental impact report for the cogeneration project in September 2019[169] - The company has two emission outlets for nitrogen oxides, with a total emission of 43.9 tons per year, which is below the regulatory limit[167]

Financial Performance - Operating income decreased by 10.21% to ¥76,861,147.27 for the current period, and by 13.07% to ¥220,485,654.60 year-to-date[8] - Net profit attributable to shareholders decreased by 46.39% to ¥9,839,666.26 for the current period, and by 40.88% to ¥35,280,914.77 year-to-date[8] - Basic earnings per share decreased by 46.67% to ¥0.08 for the current period, and by 42.00% to ¥0.29 year-to-date[8] - Net profit decreased by 40.50% to ¥35.51 million, primarily due to a reduction in operating income[17] - The company reported a significant increase in revenue for Q3 2019, achieving a total of 1.5 billion RMB, representing a year-over-year growth of 25%[22] - The net profit for Q3 2019 was CNY 35,512,662.08, down from CNY 59,680,819.50 in the same period last year, representing a decline of approximately 40.4%[58] - The total operating revenue for the year-to-date period was CNY 220,485,654.60, down 13% from CNY 253,647,847.03 in the previous year[55] Assets and Liabilities - Total assets increased by 11.48% to ¥894,558,304.56 compared to the end of the previous year[8] - Cash and cash equivalents increased by 79.85% to ¥123.53 million due to new technical transformation loans of ¥50 million[16] - Inventory decreased by 35.76% to ¥30.17 million, attributed to a reduction in finished goods and semi-finished products[16] - The company has short-term borrowings of CNY 35,000,000.00, indicating reliance on debt financing[39] - Total liabilities increased significantly to CNY 140,219,487.62 from CNY 57,136,038.36, indicating a rise in financial obligations[45] - Total equity reached ¥737,344,703.61, including retained earnings of ¥197,656,792.29[80] Cash Flow - Net cash flow from operating activities increased by 79.89% to ¥35,642,822.44 for the current period[8] - The cash flow from operating activities was CNY 237,942,382.74, down from CNY 259,458,422.75 in the previous period[64] - The net cash flow from operating activities for Q3 2019 was CNY 64,912,417.97, an increase from CNY 58,237,321.67 in Q3 2018, reflecting a growth of approximately 11.5%[65] - The total cash inflow from investment activities was CNY 405,912,933.69, compared to CNY 510,560,206.24 in the previous year, indicating a decrease of about 20.5%[66] Research and Development - Research and development expenses rose by 43.50% to ¥14.73 million, reflecting increased investment in R&D[17] - Research and development expenses increased to CNY 14,511,371.52 from CNY 10,262,697.08, indicating a focus on innovation[61] - The company plans to invest $10 million in R&D for new technologies aimed at improving product efficacy[20] Shareholder Information - The total number of common shareholders at the end of the reporting period was 13,072[12] - The largest shareholder, Shanghai Kangyi Investment Co., Ltd., holds 30.32% of shares, amounting to 36,378,000 shares[12] - The company did not conduct any repurchase transactions among the top 10 shareholders during the reporting period[13] Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2020[20] - A strategic acquisition of a local competitor was completed, which is anticipated to enhance the company's production capacity by 30%[21] - The management emphasized a commitment to sustainability, aiming for a 25% reduction in carbon footprint by 2025[21] Compliance and Governance - The management reiterated its commitment to transparency and compliance with regulatory requirements regarding related party transactions[23] - The company confirmed that there were no non-operational fund occupations by controlling shareholders or their affiliates[28] - The company has committed to not transferring benefits to other entities or individuals unfairly[27]